<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xtalpi Holdings Limited — News on 6ix</title>
<link>https://6ix.com/company/quantumpharm-inc</link>
<description>Latest news and press releases for Xtalpi Holdings Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 14:27:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quantumpharm-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683688c778dffbe2df16b693.webp</url>
<title>Xtalpi Holdings Limited</title>
<link>https://6ix.com/company/quantumpharm-inc</link>
</image>
<item>
<title>XtalPi Holdings Announces Full Year 2025 Annual Results</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-announces-full-year-2025-annual-results</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-announces-full-year-2025-annual-results</guid>
<pubDate>Wed, 25 Mar 2026 14:27:00 GMT</pubDate>
<description>XtalPi Holdings Announces Full Year 2025 Annual Results</description>
</item>
<item>
<title>XtalPi Holdings Limited to Announce 2025 Annual Results on March 25, 2026</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-limited-to-announce-2025-annual-results-on-march-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-limited-to-announce-2025-annual-results-on-march-25-2026</guid>
<pubDate>Fri, 13 Mar 2026 11:48:00 GMT</pubDate>
<description>XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its annual results for the full year ended December 31, 2025 on Wednesday, March 25, 2026, after the Hong Kong market closes.</description>
</item>
<item>
<title>XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpis-ai-robotics-platform-powers-first-clinical-milestone-for-revirs-rare-neurological-drug-rtx-117</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpis-ai-robotics-platform-powers-first-clinical-milestone-for-revirs-rare-neurological-drug-rtx-117</guid>
<pubDate>Mon, 02 Mar 2026 15:29:00 GMT</pubDate>
<description>XtalPi, a global leading AI- and robotics-driven drug discovery platform, today noted a key milestone in its collaboration with ReviR Therapeutics: dosing of the first participant in the Phase 1 clinical trial of RTX-117, an investigational small molecule being developed for Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM). The candidate, discovered and optimized using XtalPi's AI + robotics platform alongside ReviR Therapeutics' VoyageR AI platform, has also received U</description>
</item>
<item>
<title>Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF</title>
<link>https://6ix.com/company/quantumpharm-inc/news/leading-automation-capabilities-xtalpi-recognized-121400189</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/leading-automation-capabilities-xtalpi-recognized-121400189</guid>
<pubDate>Mon, 09 Feb 2026 12:14:00 GMT</pubDate>
<description>Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D) platform, announced the successful deployment of its automated formulation stability testing workstation at BASF, a world-renowned giant in the chemical industry. This collaboration enables BASF to build an end‑to‑end automated system that i</description>
</item>
<item>
<title>XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-convenes-global-experts-to-shape-the-future-of-molecular-glue-drug-discovery-from-serendipity-to-precision</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-convenes-global-experts-to-shape-the-future-of-molecular-glue-drug-discovery-from-serendipity-to-precision</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically "undruggable" protein targets.</description>
</item>
<item>
<title>XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-subsidiary-ailux-announces-strategic-collaboration-with-lilly-to-advance-bispecific-antibody-development</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-subsidiary-ailux-announces-strategic-collaboration-with-lilly-to-advance-bispecific-antibody-development</guid>
<pubDate>Wed, 05 Nov 2025 10:00:00 GMT</pubDate>
<description>Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.</description>
</item>
<item>
<title>XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-ai-drug-discovery-collaboration-reaches-milestone-as-pharmaengines-novel-prmt5-inhibitor-pep08-receives-clinical-trial-approvals</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-ai-drug-discovery-collaboration-reaches-milestone-as-pharmaengines-novel-prmt5-inhibitor-pep08-receives-clinical-trial-approvals</guid>
<pubDate>Tue, 09 Sep 2025 12:42:00 GMT</pubDate>
<description>XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia's Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone tri</description>
</item>
<item>
<title>XtalPi Holdings Announces 2025 Interim Results</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-announces-2025-interim-results</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-announces-2025-interim-results</guid>
<pubDate>Wed, 27 Aug 2025 14:26:00 GMT</pubDate>
<description>Key Highlights from the Financial Report:</description>
</item>
<item>
<title>XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-signs-mou-with-dong-a-st-for-joint-research-and-development-of-immunology-and-inflammation-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-signs-mou-with-dong-a-st-for-joint-research-and-development-of-immunology-and-inflammation-therapies</guid>
<pubDate>Wed, 20 Aug 2025 00:00:00 GMT</pubDate>
<description>XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases.</description>
</item>
<item>
<title>XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-limited-to-announce-2025-interim-results-on-august-27-2025</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-holdings-limited-to-announce-2025-interim-results-on-august-27-2025</guid>
<pubDate>Mon, 18 Aug 2025 10:59:00 GMT</pubDate>
<description>XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its interim results for the six months ended June 30, 2025 on Wednesday, August 27, 2025, after the Hong Kong market closes.</description>
</item>
<item>
<title>XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-dovetree-announce-landmark-dollar6-billion-ai-drug-discovery-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-dovetree-announce-landmark-dollar6-billion-ai-drug-discovery-collaboration</guid>
<pubDate>Thu, 07 Aug 2025 00:05:00 GMT</pubDate>
<description>XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.</description>
</item>
<item>
<title>XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-pfizer-expand-strategic-collaboration-to-advance-ai-driven-drug-discovery-and-materials-science-simulations</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-pfizer-expand-strategic-collaboration-to-advance-ai-driven-drug-discovery-and-materials-science-simulations</guid>
<pubDate>Mon, 30 Jun 2025 01:28:00 GMT</pubDate>
<description>XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery. This initiative is focused on improving the accuracy of advanced physics-based methods with the speed, scalability, and expansive coverage of cutting-edge AI models to o</description>
</item>
<item>
<title>XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-announces-strategic-collaboration-with-harvard-professor-gregory-verdines-dovetree-llc-to-advance-novel-therapeutics-using-airobotics-drug-discovery-platform</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-announces-strategic-collaboration-with-harvard-professor-gregory-verdines-dovetree-llc-to-advance-novel-therapeutics-using-airobotics-drug-discovery-platform</guid>
<pubDate>Mon, 23 Jun 2025 01:10:00 GMT</pubDate>
<description>XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveT</description>
</item>
<item>
<title>XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-announces-strategic-acquisition-of-liverpool-chirochem-lcc-unlocking-unprecedented-power-in-chemical-space-exploration</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-announces-strategic-acquisition-of-liverpool-chirochem-lcc-unlocking-unprecedented-power-in-chemical-space-exploration</guid>
<pubDate>Fri, 13 Jun 2025 07:00:00 GMT</pubDate>
<description>XtalPi, a leading life sciences and new materials R&D platform powered by quantum physics, AI and robotics, today announced its acquisition of Liverpool ChiroChem (LCC), a pioneer in automated chiral chemistry technologies. This strategic merger will enhance XtalPi's ability to explore and synthesize novel chemical space with speed and precision, accelerating innovation for pharmaceutical, materials, agricultural, and specialty chemical applications. The acquisition underscores XtalPi's commitme</description>
</item>
<item>
<title>XtalPi and Kula Bio Forge Multi-Million USD Collaborative R&D Agreement to Advance AI-Driven Microbial Fertilizers in China and the Middle East</title>
<link>https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-kula-bio-forge-multi-million-usd-collaborative-randd-agreement-to-advance-ai-driven-microbial-fertilizers-in-china-and-the-middle-east</link>
<guid isPermaLink="true">https://6ix.com/company/quantumpharm-inc/news/xtalpi-and-kula-bio-forge-multi-million-usd-collaborative-randd-agreement-to-advance-ai-driven-microbial-fertilizers-in-china-and-the-middle-east</guid>
<pubDate>Fri, 28 Mar 2025 13:31:00 GMT</pubDate>
<description>XtalPi (2228.HK) today announced the official signing of a strategic R&D collaboration agreement with U.S.-based Kula Bio in Boston. This partnership initiates a joint research initiative worth multi-million USD, focused on developing the next generation of microbial organic fertilizers to provide breakthrough solutions for agriculture in arid and desert regions. By integrating artificial intelligence (AI), microbial technology, and automation, the collaboration aims to enhance agricultural prod</description>
</item>
</channel>
</rss>